Archer et al. have performed a proteomic and phosphoproteomic analysis of 45 medulloblastoma samples and observed a molecular heterogeneity of Group 3 tumors, with the identification of two subgroups, termed G3a and G3b: the proteomic features of G3a suggests a MYC-activated signature; however, only a minority of these tumors contained amplified MYC, while the majority displayed various post-translational modifications of MYC, occurring at the level of various sites of the molecule [413]. This evidence concerns the gene MYC and medulloblastoma.